Vinaxanthone shows selective inhibitory activity against phospholipase C (PLC) from rat brain, mutine colon 26 Adenocarcinoma and murine fibroblasts NIH3T3 with IC50s being 5.4, 9.3 and 44 μM, respectively[1].
Vinaxanthone (0.1 mg/mL, 24 h) enhances peripheral nerve regeneration and induces small amounts of neovascularization growth into the cornea[4].
Vinaxanthone (0.5 μM, 20 min) may protects from Dox-induced podocyte apoptosis[5].
Vinaxanthone (0.1-1 μM, 24 h) ameliorates the TGF-β1-induced tubular cell characteristic change[6].
Vinaxanthone (SM-345431) (0.1 mg/mL, Subconjunctival injections, every 2 days, 3 weeks) accelerates peripheral nerve regeneration and sensitivity in a murine corneal transplantation model[4].
Vinaxanthone (SEMA3A-I) (20 µg, i.p.) protects from Doxorubicin -induced podocyte injury through an anti-apoptosis mechanism in mouse model of Doxorubicin -induced podocytopathy[5].
References:
[1]. Masahiro Aoki, et al. Structure of a novel phospholipase C inhibitor, vinaxanthone (Ro 09-1450), produced by penicillium vinaceum. Tetrahedron Letters. 1991, 32 (36):4737-4740.
[2]. Liang Zhang, et al. Rewiring of regenerated axons by combining treadmill training with semaphorin3A inhibition. Mol Brain. 2014 Mar 10; 7:14.
[3]. Zheng CJ, et al. Vinaxanthone, a new FabI inhibitor from Penicillium sp. J Antimicrob Chemother. 2009 May;63(5):949-53.
[4]. Omoto M, Yoshida S, Miyashita H, Kawakita T, Yoshida K, Kishino A, Kimura T, Shibata S, Tsubota K, Okano H, Shimmura S. The semaphorin 3A inhibitor SM-345431 accelerates peripheral nerve regeneration and sensitivity in a murine corneal transplantation model. PLoS One. 2012;7(11):e47716.
[5]. Sang Y, et al. Semaphorin3A-Inhibitor Ameliorates Doxorubicin-Induced Podocyte Injury. Int J Mol Sci. 2020 Jun 8;21(11):4099.
[6]. Sang Y, et al. Semaporin3A inhibitor ameliorates renal fibrosis through the regulation of JNK signaling. Am J Physiol Renal Physiol. 2021 Dec 1;321(6):F740-F756.